The Antitumor Efficacy of Astragalus membranaceus and Its Active Constituents: A Systematic Review of Preclinical Evidence
Drugs and Drug Candidates · 24.07.2026 · 5 (3) · 42
DOI: 10.3390/ddc5030042 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Drugs and Drug Candidates, online erschienen am 24.07.2026. Verfasst von Chung-Wai Yu und 4 weiteren Autor:innen. Die Arbeit nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Food and Health Bureau HKSAR, Guangdong-Hong Kong-Macao New Drug Screening Joint Laboratory, Institute of Chinese Medicine CUHK.
Abstract (Originalsprache)
Backgrounds: Astragalus membranaceus (AM), a traditional Chinese medicinal herb, has garnered interest for its potential in anticancer therapy. Preclinical evidence suggests that AM inhibits tumor growth and could mitigate the adverse effects associated with conventional treatments. However, a comprehensive review of its efficacy across various cancer types is lacking.
Objectives
This systematic review evaluates the preclinical evidence for the antitumor efficacy of AM and its active components to inform future clinical translation.
Methods
A systematic literature search was conducted in PubMed, EMBASE, and Web of Science from their earliest records to February 2026 to identify relevant studies. Studies reporting on the antitumor effects of AM or its constituents in murine models were included.
Results
Seventy-six studies met the inclusion criteria. The most frequently investigated compounds were formononetin (21 studies), Astragaloside IV (20 studies), and Astragalus polysaccharide (16 studies). The evidence indicates that these compounds, both as monotherapies and in combination with standard chemotherapy, can inhibit tumor growth and potentiate antitumor efficacy.
Conclusions
AM and its bioactive constituents exhibit promising anticancer effects against solid tumors, including breast, lung, hepatocellular, and colorectal carcinomas in preclinical models. Clinical investigation is warranted to confirm the utility of AM for cancer therapy.
Förderung
- Food and Health Bureau HKSAR
- Guangdong-Hong Kong-Macao New Drug Screening Joint Laboratory
- Institute of Chinese Medicine CUHK
Zitieren
APA
Yu, C., Chan, Y., Cho, W. C., Zuo, Z., & To, K. K. W. (2026). The Antitumor Efficacy of Astragalus membranaceus and Its Active Constituents: A Systematic Review of Preclinical Evidence. Drugs and Drug Candidates, 5(3), 42. https://doi.org/10.3390/ddc5030042
Vancouver
Yu C, Chan Y, Cho WC, Zuo Z, To KKW. The Antitumor Efficacy of Astragalus membranaceus and Its Active Constituents: A Systematic Review of Preclinical Evidence. Drugs and Drug Candidates. 2026;5(3):42. doi:10.3390/ddc5030042
BibTeX
@article{Yu2026,
author = {Yu, Chung-Wai and Chan, Yuet-Wa and Cho, William C. and Zuo, Zhong and To, Kenneth K. W.},
title = {The Antitumor Efficacy of Astragalus membranaceus and Its Active Constituents: A Systematic Review of Preclinical Evidence},
journal = {Drugs and Drug Candidates},
year = {2026},
volume = {5},
number = {3},
pages = {42},
doi = {10.3390/ddc5030042}
}
EUVIMED